Drug Trial Radar · NCT03613662
A Research Study to Characterize the Pharmacodynamics and Safety of Repeat Dose SP-102
Last checked: Nov 19, 2026Latest source record: Jan 13, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
19
Actual
Start
Jul 13, 2018
Primary completion
Mar 15, 2019
Study completion Mar 15, 2019
Sponsor
- Lead sponsor
- Semnur Pharmaceuticals, Inc.Industry
- Sponsor type
- Industry
- Collaborators
- Worldwide Clinical Trials; Scilex Pharmaceuticals, Inc.
- First posted
- Aug 3, 2018
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is an open-label, single-arm, repeat dose study to characterize the pharmacodynamics and safety/tolerability of SP-102 administered by epidural injection.
Conditions
- Lumbosacral Radicular Pain
Interventions
SP-102Drug
Injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in Plasma Cortisol Concentrations From BaselineTime frame: 12 Weeks
- Change in Blood Glucose Levels From BaselineTime frame: 12 Weeks
- Change in White Blood Cell (WBC) Levels From BaselineTime frame: 12 Weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Semnur Research Site 1
Boise, Idaho
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.